ATE506945T1 - Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität - Google Patents

Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität

Info

Publication number
ATE506945T1
ATE506945T1 AT05808933T AT05808933T ATE506945T1 AT E506945 T1 ATE506945 T1 AT E506945T1 AT 05808933 T AT05808933 T AT 05808933T AT 05808933 T AT05808933 T AT 05808933T AT E506945 T1 ATE506945 T1 AT E506945T1
Authority
AT
Austria
Prior art keywords
memantine
namenda
impulsivity
treat autism
ocd
Prior art date
Application number
AT05808933T
Other languages
English (en)
Inventor
Eric Hollander
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Application granted granted Critical
Publication of ATE506945T1 publication Critical patent/ATE506945T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT05808933T 2004-09-20 2005-09-19 Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität ATE506945T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61153404P 2004-09-20 2004-09-20
PCT/US2005/033467 WO2006034187A2 (en) 2004-09-20 2005-09-19 Use of memantine (namenda) to treat autism, compulsivity, and impulsivity

Publications (1)

Publication Number Publication Date
ATE506945T1 true ATE506945T1 (de) 2011-05-15

Family

ID=36090565

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05808933T ATE506945T1 (de) 2004-09-20 2005-09-19 Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität

Country Status (10)

Country Link
US (2) US8461148B2 (de)
EP (1) EP1793671B1 (de)
JP (1) JP5289765B2 (de)
AT (1) ATE506945T1 (de)
AU (1) AU2005286943A1 (de)
CA (1) CA2580619C (de)
DE (1) DE602005027714D1 (de)
DK (1) DK1793671T3 (de)
ES (1) ES2367868T3 (de)
WO (1) WO2006034187A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
US20080194698A1 (en) * 2005-03-07 2008-08-14 Michael Hermanussen Nmda Receptor Antagonists in the Medical Intervention of Metabolic Disorders
AU2006291134C1 (en) 2005-09-12 2013-08-15 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
US9427419B2 (en) 2005-09-12 2016-08-30 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (DMSO)
WO2007061868A2 (en) * 2005-11-17 2007-05-31 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors
US20080108643A1 (en) * 2006-11-03 2008-05-08 Forest Laboratories Holdings Limited Method for treating autism
WO2009004440A2 (en) * 2007-06-29 2009-01-08 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
WO2009035473A2 (en) * 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
EP2111858A1 (de) * 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Neue Behandlung für Morbus Alzheimer
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
CN102070463A (zh) * 2009-06-11 2011-05-25 辽宁利锋科技开发有限公司 具有金刚烷结构药物美金刚胺及其衍生物和类似物抗肿瘤新适应症的应用
US9839609B2 (en) 2009-10-30 2017-12-12 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis
WO2011123695A1 (en) * 2010-03-31 2011-10-06 Abela Pharmaceuticals, Inc. Dimethy sulfoxxide (dmso) formulations for treating autism
US9708366B2 (en) * 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
EP2836213B1 (de) * 2012-04-14 2018-07-04 Intra-Cellular Therapies, Inc. Kondensierte gamma carboline
US20130296430A1 (en) * 2012-05-03 2013-11-07 Antonio Hardan Compositions and methods for treating autism and autism spectrum disorder
CA2929286A1 (en) * 2012-11-28 2014-06-05 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
KR101424514B1 (ko) 2013-01-02 2014-07-31 건국대학교 산학협력단 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도
PL2968320T3 (pl) 2013-03-15 2021-05-17 Intra-Cellular Therapies, Inc. Związki organiczne
KR20230023817A (ko) 2013-12-03 2023-02-17 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
JP6419826B2 (ja) * 2013-12-13 2018-11-07 ピエール、ファーブル、メディカマン 自閉症スペクトラム障害の治療のためのドーパミンｄ３受容体拮抗薬としてのクロモン誘導体
RU2020123764A (ru) 2014-04-04 2020-08-05 Интра-Селлулар Терапиз, Инк. Органические соединения
EP3085366A1 (de) * 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda-antagonisten zur behandlung von mentalen erkrankungen mit auftreten von aggressivem und/oder impulsivem verhalten
PL3407888T3 (pl) 2016-01-26 2021-08-30 Intra-Cellular Therapies, Inc. Związki pirydopirolochinoksaliny, ich kompozycje i zastosowania
EP3888656A1 (de) 2016-03-25 2021-10-06 Intra-Cellular Therapies, Inc. Deuterierte heterozyklische gamma-carboline verbindungen und deren verwendung zur behandlumg oder prophylaxe einer störung des zentralen nervensystems.
EP3436083A4 (de) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Neuartige zusammensetzungen und verfahren
EP3449402A1 (de) * 2016-04-29 2019-03-06 Supernus Pharmaceuticals, Inc. Verfahren, system und kit zur überwachung, diagnose und behandlung von impulsiven aggressionen
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
US10493045B2 (en) * 2016-12-14 2019-12-03 Ru-Band Lu Method for treating alcohol dependence or alcohol abuse
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
MX2021013640A (es) 2017-03-24 2022-08-31 Intra Cellular Therapies Inc Composiciones novedosas y metodos.
CA3071137A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Prodrugs of substituted heterocycle fused gamma-carbolines
IL272249B2 (en) 2017-07-26 2023-11-01 Intra Cellular Therapies Inc organic compounds
CN111356452A (zh) * 2017-08-01 2020-06-30 斯图尔特·A·利普顿 用于治疗神经病况的方法和组合物
MX2020013335A (es) 2018-06-08 2021-05-27 Intra Cellular Therapies Inc Metodos novedosos.
JP7457000B2 (ja) 2018-08-31 2024-03-27 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
CA3108553A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
US20240197652A1 (en) * 2021-05-25 2024-06-20 Awakn Ls Europe Holdings Limited Ketamine in the treatment of behavioral addictions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US6387956B1 (en) * 1999-03-24 2002-05-14 University Of Cincinnati Methods of treating obsessive-compulsive spectrum disorders
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
AU2002354041A1 (en) * 2001-11-06 2003-05-19 John L. Haracz Antimnemonic therapy for hypermemory syndromes
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism

Also Published As

Publication number Publication date
AU2005286943A1 (en) 2006-03-30
WO2006034187A2 (en) 2006-03-30
WO2006034187A3 (en) 2006-09-14
DE602005027714D1 (de) 2011-06-09
CA2580619C (en) 2013-11-12
CA2580619A1 (en) 2006-03-30
EP1793671A2 (de) 2007-06-13
US8461148B2 (en) 2013-06-11
EP1793671A4 (de) 2008-03-12
JP5289765B2 (ja) 2013-09-11
US20080249082A1 (en) 2008-10-09
US20140088083A1 (en) 2014-03-27
DK1793671T3 (da) 2011-08-22
JP2008513491A (ja) 2008-05-01
EP1793671B1 (de) 2011-04-27
ES2367868T3 (es) 2011-11-10

Similar Documents

Publication Publication Date Title
ATE506945T1 (de) Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
ATE497809T1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
ATE324908T1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
ATE410235T1 (de) Behandlung von ballastwasser
ATE355054T1 (de) Verfahren und verbindungen zur behandlung der depression
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
BR0209614A (pt) Métodos para tratamento de um mamìfero sofrendo de distúrbio obsessivo-compulsivo (ocd) ou distúrbios relacionados a ocd, e para redução ou eliminação de comportamentos associados com ocd ou distúrbios relacionados a ocd em um mamìfero sofrendo de tais distúrbios
NO20061383L (no) Substituerte aryl cykloalkanolderivater og fremgangsmater for anvendelse derav
ATE539755T1 (de) Verwendung von selektiven chloridkanalmodulatoren zur behandlung des alkohol- und/oder stimulans missbrauches
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
DE602005013805D1 (de) Verwendung von il-17f zur behandlung und/oder prävention von neurologischen erkrankungen
ATE384520T1 (de) Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitas
DE60108241D1 (de) Felabamat-derivate zur behandlung von neuropathischem schmerz
ATE516813T1 (de) Verfahren und verbindungen zur behandlung von diabetes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties